# Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol

> **NCT00422552** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 30 (—)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Indacaterol (QAB149)

## Key facts

- **NCT ID:** NCT00422552
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (—)
- **Last updated:** 2007-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422552, "Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00422552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*